AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05344183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser
Description: A laser will be used in the quadriceps and gluteus medius muscles with the following parameters described for muscle recovery: dose of 40 J for the gluteus medius muscle, 180 J for the quadriceps muscle; power from 50 to 200 mW per diode (for single probes), 10 to 35 mW per diode (for cluster probes). The full power of the device cannot lead to thermal effects; Wavelengths of 950 nm (infrared).
Study NCT05344183 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-level laser
Description: A laser will be used in the quadriceps and gluteus medius muscles with the following parameters described for muscle recovery: dose of 40 J for the gluteus medius muscle, 180 J for the quadriceps muscle; power from 50 to 200 mW per diode (for single probes), 10 to 35 mW per diode (for cluster probes). The full power of the device cannot lead to thermal effects; Wavelengths of 950 nm (infrared).
Study NCT05006157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViaOne device
Description: ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.
Study NCT04457089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
Study NCT05722535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Media Check-In (FMC)
Description: An interactive, web-based tool to support within-family media use planning will be developed and shared with families.
Study NCT05048433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: implementation strategy for active learning to promote physical activity
Description: The experimental arm includes using a multifaceted implementation strategy to support the use of active learning approaches. The strategy will consist of a series of skills-based staff trainings, identifying program champions to help lead efforts within the school, establishing an audit and feedback system to monitor the use of active learning, and a reinforcement system to recognize staff who are successfully implementing.
Study NCT05048433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Implementation support
Description: Usual support consists of the potential to access general resources from the district wellness department. These resources include access to funds to send staff to external trainings and general guidance for how to use active learning approaches.
Study NCT04740385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung auscultation
Description: auscultation of air entry through chest wal
Study NCT05418582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008 and intraconazole
Description: All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
Study NCT05418582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008 and carbamazepine
Description: All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
Study NCT04102254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANT recording and stimulation
Description: In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
Study NCT05183854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 20-valent Conjugate Vaccine
Description: Given IM
Study NCT04740385 — intervention group
Intervention type: DEVICE
Intervention: Fiberoptic bronchoscopy
Description: Checking correct double lumen position through direct vision using fiberoptic bronchoscopy
Study NCT04740385 — intervention group
Intervention type: DEVICE
Intervention: Lung Ultrasound
Description: real time visualization of air entry to the lungs using trans-thoracic lung ultrasound
Study NCT04229329 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intensive Finger Individuation Therapy
Description: Interactive robot-mediated treatment aimed at increased individuation done repeatedly for at least1 hour per day for 2 weeks (5 training days a week).
Study NCT04229329 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Intensive non-directed finger movement therapy
Description: Interactive robot-mediated treatment not aimed specifically at increased individuation done repeatedly for at least 1 hour per day for 2 weeks (5 training days per week)
Study NCT02586831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (ATG)
Description: 2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
Study NCT02586831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: 1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
Study NCT05183854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Polyvalent Vaccine
Description: Given IM
Study NCT05183854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06389877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM-302
Description: BEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD
Study NCT04634552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered SC until disease progression.
Study NCT05966155 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19
Study NCT05966155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19
Study NCT05966155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decisions support
Description: Prescribing recommendations to the provider based on the pharmacogenetic testing results
Study NCT05997875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Participants are provided with the Getting Ready: Your Vascular Access Journey video and brochure about hemodialysis vascular access. The video is available for viewing via smartphone or computer. Both the brochure and video were created with input from patients with chronic kidney disease.
Study NCT05997875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants receive coaching with telehealth-based motivational interviewing designed to prepare participants to move forward with vascular access creation. Motivational interviewing will consist of a minimum of 3 and maximum of 8 telehealth sessions with a coach. The coach will use patient-centered communication skills to work though the stages of pre-contemplative, contemplative, preparation, action, and maintenance of an arteriovenous vascular access.
Study NCT05997875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants receive the non-standardized vascular access counseling and referral to the chronic kidney disease education class that comprises the standard care provided by their nephrology clinic.
Study NCT05997875 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants receive the non-standardized vascular access counseling and referral to the chronic kidney disease education class that comprises the standard care provided by their nephrology clinic.
Study NCT05997875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Lists for Clinicians: System-Level Intervention
Description: Nephrologists and clinic staff receive monthly, provider-specific, lists of patients potentially appropriate for AV access planning based on eGFR thresholds and kidney failure risk. These criteria identify patients at risk for progression to dialysis and are congruent with evidence-based guidelines for optimal timing of AV access evaluation referral.
Study NCT05997875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient Lists for Clinicians: System-Level Intervention
Description: Nephrologists and clinic staff receive monthly, provider-specific, lists of patients potentially appropriate for AV access planning based on eGFR thresholds and kidney failure risk. These criteria identify patients at risk for progression to dialysis and are congruent with evidence-based guidelines for optimal timing of AV access evaluation referral.
Study NCT05189262 — intervention group
Intervention type: OTHER
Intervention: Blood and urine collection
Description: No intervention - Biological specimen collection
Study NCT06324864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: START NOW Adapted
Description: The START NOW skills-training combines aspects of cognitive behavioral therapy (CBT), motivational interviewing (MI), dialectical behavior therapy (DBT), Acceptance and Commitment Therapy (ACT) and trauma-sensitive care. Studies in different contexts have shown START NOW's effectiveness in terms of reducing behavioral problems, reducing hospitalization rates, improving mental health functioning and increasing satisfaction rates. The culturally adapted version will be contextually adapted to different cultural backgrounds and the experience of migration. In ten sessions, participants learn about emotions and are introduced to the START NOW skills. These skills, called SLOW DOWN, TAKE A STEP BACK, ACCEPT, RESPECT and TAKE ACTION, are strategies or techniques that can be used to better manage stress and difficult emotions.
Study NCT05963074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsules will be administered orally.
Study NCT05963074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered orally.
Study NCT06492005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
Study NCT06492005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitior
Description: Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol
Study NCT05642182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFA002
Description: Study drug formula without excipient
Study NCT05642182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFA002
Description: Study Drug SFA002 with excipient (Propionate)
Study NCT05563038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scrambler Therapy
Description: Scrambler Therapy is a non-invasive neuromodulator treatment that focuses on relieving chronic pain through the sending of non-pain signals to the brain through the afferent pain sensory nerves. The signals given off by the scrambler therapy machine are intended to mimic neuronal action potentials through the synthesis of 16 unique waveforms that in combination forms a patient specific cutaneous electrostimulation to reduce pain. These information packets are then carried by the afferent C-fibers, an established system that modulates the sensations received instead of blocking them. The modulated signals are received as nonpainful and endogenous by the central nervous system.
Study NCT05563038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medication Management
Description: Medications such as: gabapentin, duloxetine and Lyrica are all FDA approved for treatment of neuropathic pain, particularly that caused by diabetes.
Study NCT04368949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepping-Up
Description: The intervention group will receive STEPPING-UP, a virtual 12-week, multicomponent intervention that includes tailored task-oriented motor learning exercise and a mobility self-management (SM) program.
Study NCT04368949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Coaching Walking Program
Description: The participants assigned to this group will receive a 12-week Telephone-Based Coaching Walking Program (TELE) delivered by a PT who will help participants set short and long term walking goals.
Study NCT04368949 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chair-Based Yoga Program
Description: Participants assigned to this group will receive a virtual 12-week Chair-Based Yoga Program (YOGA), a group-based exercise control where participants will undertake a seated exercise program that includes: warm up, seated and standing yoga poses, cool down.
Study NCT04754139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WeChat mobile mini-application
Description: Sexual health education and the role of PrEP
Study NCT05022849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75229414
Description: JNJ-75229414 infusion will be administered intravenously.
Study NCT05022849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bridging Therapy
Description: Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.
Study NCT05178992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socially Assistive Robot Activity
Description: Participants will attend two weekly sessions with robot activities. Each session will last 30 minutes. Participants will attend robot sessions for 8 weeks.
Study NCT02586831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 2 mg administered subcutaneously weekly for up to 52 weeks.
Study NCT02586831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 50 mg administered subcutaneously once a month for 1 year.
Study NCT02586831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ATG Placebo
Description: ATG placebo mimicking Thymoglobulin administered intravenously.
Study NCT02586831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IL-2 Placebo
Description: IL-2 placebo mimicking Aldesleukin administered subcutaneously.
Study NCT02586831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab Placebo
Description: Placebo mimicking Adalimumab administered subcutaneously.
Study NCT02586831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide Placebo
Description: Placebo mimicking Exenatide administered subcutaneously.
Study NCT04759508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flax Oil Capsule
Description: Flaxseed with brand name Flax Oil Capsule will be administered to subjects receiving antihypertensives.
Study NCT05178992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Socially Assistive Robot Activity
Description: Participants will attend two weekly sessions with robot activities. Each session will last 30 minutes. Participants will attend robot sessions for 8 weeks.
Study NCT04759508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Soya Oil Capsule
Description: Placebo capsule filled with soya oil and inert(inactive) substances will be administered to subjects remaining anti hypertensives.
Study NCT05670054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
Description: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
Study NCT04122105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
Study NCT04122105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
Study NCT05936879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Group A: Intervention group will be treated with Inspiratory muscle training and early ambulation and routine physical therapy including ankle pumps,hand pumps isometrics of upper and lower limbs after surgery
Study NCT05936879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs.
Description: Group B: Control group routine physical therapy including ankle pumps, hand pumps isometrics of upper and lower limbs
Study NCT06436378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention in person
Description: The music intervention consists of listening to two or three pieces of music chosen by each participant that bring them a sense of well-being. One of the two music intervention sessions will be preceded by a moment of relaxation, during which participants will be asked to focus their attention on their breathing, on relaxation, and on the process of self-absorption. This intervention, preceded by a brief moment of relaxation, will take place during the first session for half of the participants and during the second session for the other half.
Study NCT06312683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 MG Oral Tablet [XIFAXAN]
Description: Rifaximin 550 MG Oral Tablet \[XIFAXAN\] Taken twice a day for up to 365 days
Study NCT05422638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RBSTE
Description: 8-week health promotion group focused on supporting coping with racism and empowerment
Study NCT05422638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PCT
Description: 8-week health promotion group focused on providing support and facilitating problem solving
Study NCT04591093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated
Description: Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated
Study NCT05789888 — intervention group
Intervention type: GENETIC
Intervention: MT-ATP6 mtDNA gene variability in obesity and normal body weight patients.
Description: As part of the research, the MT-ATP6 gene was tested in order to influence the modulation of the amount of fat contained.
Study NCT05789888 — intervention group
Intervention type: GENETIC
Intervention: SCD gene variability in obesity and normal body weight patients.
Description: As part of the research, the SCD gene was tested in order to influence the modulation of the amount of fat contained.
Study NCT05789888 — intervention group
Intervention type: OTHER
Intervention: Finding TOFI and FOTI phenotypes in participants with obesity and normal weight.
Description: As part of the research, we measured the amount of VAT and SAT and calculate VAT/SAT ratio as a marker to determine the phenotype of fat tissue.
Study NCT06392477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody
Study NCT04628494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Following mandatory pre-medication subject will be administered epcoritamab as a subcutaneous injection.
Study NCT04628494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice Chemotherapy
Description: Following mandatory pre-medication subject will be administered intravenously either BR or R-GemOx.
Study NCT05445232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.
Study NCT05445232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.
Study NCT05445232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Administered orally.
Study NCT05445232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Administered orally.
Study NCT06507722 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Timing of OGTT
Description: In Aim 1, timing of oral glucose tolerance test will be altered.
Study NCT06507722 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Timing of Standardized Meal
Description: In Aim 2, timing of a standardized meal will be altered.
Study NCT05692960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnotic Relaxation Intervention (HRI)
Description: HRI is a combination intervention (Replens™ vaginal moisturizer device and hypnotic relaxation behavioral intervention)
Study NCT05692960 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vulvovaginal Atrophy (VVA)
Description: VVA is a standard of care intervention (Replens™ vaginal moisturizer device)
Study NCT05686551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tominersen 60 mg
Description: 60 mg tominersen administered intrathecally every 16 weeks
Study NCT05686551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered intrathecally every 16 weeks
Study NCT05686551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tominersen 100 mg
Description: 100 mg tominersen administered intrathecally every 16 weeks